

FINAL REPORT

SM-102 Bacterial Reverse Mutation Test in Salmonella Typhimurium and Escherichia Coli

SPONSOR:
Moderna Therapeutics, Inc.
Technology Square, Third Floor
Cambridge, MA 02130

USA 200 Technology Square, Third Floor

River Laboratories Mon Senneville Site (CR MTL 22022 Transcanadienne Senneville, QC H9X 3R3 Canada Charles River Laboratories Montreal ULC

TABLE OF CONTENTS

LIST OF TABLES	3
LIST OF APPENDICES	4
COMPLIANCE STATEMENT	5
COMPLIANCE STATEMENT QUALITY ASSURANCE STATEMENT 1. RESPONSIBLE PERSONNEL 1.1. Test Facility 1.2. Individual Scientists (IS) at Test Facility 2. SUMMARY 3. INTRODUCTION 4. MATERIALS AND METHODS 4.1. Test and Reference Items 4.1.1 Test Item 4.1.2. Reference Items 4.2. Test Item Characterization 4.3. Analysis of Test Item 4.4. Test Item Inventory and Disposition 4.5. Dose Formulation and Analysis 4.5.1. Preparation of Reference Items 4.5.2. Preparation of Test Item 4.5.3. Sample Collection and Analysis 4.6. Test System 4.6.1. Justification for Test System and Dose Level Selection.	6
1 RESPONSIBLE PERSONNEL	Varie 7
1 1 Test Facility	7
1.2. Individual Scientists (IS) at Test Facility	
2 SUMMARY	8
2 INTRODUCTION	
5. INTRODUCTION	
4. MATERIALS AND METHODS	9
4.1. Test and Reference Items	9
4.1.1. Test Item	9
4.1.2. Reference Items	9
4.2. Test Item Characterization	10
4.3. Analysis of Test Item	10
4.4. Test Item Inventory and Disposition	10
4.5. Dose Formulation and Analysis	10
4.5.1. Preparation of Reference Items	10
4.5.2. Preparation of Test Item	11
4.5.3. Sample Collection and Analysis,	
4.6. Test System	12
4.6.1. Justification for Test System and Dose Level Selection	12
4.7. S9 Mix	
4.8. Sterility Check and Spontaneous Mutation Rates	
4.9. Plate Incorporation Method	
4.10. Experimental Design	13
5. COMPUTERIZED SYSTEMS	13
6. EVALUATION AND INTERPRETATION OF RESULTS	14
6.1. Assay Acceptance Criteria:	14
6.2. Interpretation of Results	15
7. RETENTION OF RECORDS	15
8. RESULTS	
8.2. Bacterial Mutation Test	
9. CONCLUSION	17

LIST OF TABLES

		LIST OF TABLES
r ·	Table 1	SM-102 - Plate Incorporation Assay in the Absence of S9 Mix18
ŗ	Table 2	SM-102 - Plate Incorporation Assay in the Presence of S9 Mix20
r	Table 3	Positive Controls for the Plate Incorporation Assay22
This docum	Table 3	SM-102 - Plate Incorporation Assay in the Absence of S9 Mix

LIST OF APPENDICES

Appendix 1	Study Plan, Amendment and Deviations	23
Appendix 2	Test Item Characterization	53
Appendix 3	Historical Negative and Positive Control Results	566
Appendix 4	Dose Formulation Analysis Report	58
This document cannot be	Study Plan, Amendment and Deviations Test Item Characterization Historical Negative and Positive Control Results Dose Formulation Analysis Report Dose Formulation Analysis	ons or vali

COMPLIANCE STATEMENT

The study was performed in accordance with the OECD Principles of Good Laboratory Practice and as accepted by Regulatory Authorities throughout the European Union, United States of America (FDA), Japan (MHLW), and other countries that are signatories to the OECD Mutual Acceptance of Data Agreement.

Exceptions from the above regulations are listed below.

- Characterization of the Test Item was performed by the Sponsor subcontractor according to
 established SOPs, controls and approved test methodologies to ensure integrity and validity
 of the results generated; these analyses were not conducted in compliance with the GLP or
 GMP regulations.
- Stability testing of the supplied Test Item was not determined in this study. It will be
 performed by the Sponsor subcontractor at a laboratory that follows FDA Good
 Manufacturing Practice (GMP) regulations.

This study was conducted in accordance with the procedures described herein. All deviations authorized/acknowledged by the Study Director are documented in the Study Records. The report represents an accurate and complete record of the results obtained.

There were no deviations from the above regulations that affected the overall integrity of the study or the interpretation of the study results and conclusions.

ema authorison		
	Date:	
MSc Study Director MSc Study Director MSc Study Director	Dutc	
ant cannot be the		

QUALITY ASSURANCE STATEMENT

Study Number: 9601567

This Study has been audited by Quality Assurance in accordance with the applicable Good Laboratory Practice regulations. Reports were submitted in accordance with SOPs as follows:


QA INSPECTION DATES

Dates Findings Submitted to:

Date(s) of Audit	Phase(s) Audited	Study Director	Study Director Management
12-Sep-2016	Final Study Plan	22-Sep-2016	22-Sep-2016
12-Sep-2016	Dose Preparation	22-Sep-2016	22-Sep-2016
22-Sep-2016	Study Plan Amendment 1	22-Sep-2016	22-Sep-2016
01-Nov-2016 - 02-Nov-2016	Data Review - Analytical Chemistry	04-Nov-2016	04-Nov-2016
01-Nov-2016 - 02-Nov-2016	Final Phase Report - Dose Formulation Analysis	04-Nov-2016	04-Nov-2016
08-Nov-2016 - 09-Nov-2016	Data Review - In Vitro Sciences	09-Nov-2016	09-Nov-2016
08-Nov-2016 - 09-Nov-2016	Final Report	09-Nov-2016	09-Nov-2016

In addition to the above-mentioned audits, process-based and/or routine facility inspections were also conducted during the course of this study. Inspection findings, if any, specific to this study were reported by Quality Assurance to the Study Director and Management and listed as a Phase Audit on this Quality Assurance Statement.

The Final Report has been reviewed to assure that it accurately describes the materials and methods, and that the reported results accurately reflect the raw data.



Date

1. RESPON	SIBLE PERSONNEL		
1.1. Test Factorium Study Director	SIBLE PERSONNEL Sility Management Tal Scientists (IS) at Test Facilitation Analysis Signature of the support any marketing purious in the support and support an	MSc	weke o
Test Facility M	fanagement	PhD, DABT	ionsiti
1.2. Individu	nal Scientists (IS) at Test Facili	ty	Jaliatie
Dose Formula	tion Analysis	BSc	SOL
			Sione
		, Õ	tien.
		and a	201
		an ancembe	
		icatio, Osc	
		of applian	
	4C	Pa. 6 2110/1/200	
	a.e.ii	norishohis	
	Suc an	70	
	alke till E		
	Whichlatic		
	ort all People		
	enblinge,		
	30,000		
	120 G.		
oro th			
at call.			
Imel			
, 6 40 CU			
This			

2. SUMMARY

The objective of this study was to determine the potential genotoxicity of SM-102, using the bacterial reverse mutation test.

The experimental design was as follows:

Text Table 1
Plate Incorporation Assay

	Formulation	Dose	F: 10	Number of	Replicates	1/3/
Dose No.	Conc. (μg/mL)	Volume (μL/plate)	Final Conc. (µg/plate)	0S9	+S9	Number of Strains
Negative Control	-	100	-	3	3 200	5
1/ SM-102	19.0 ^b	83.2	1.58	3	3	5
2/ SM-102	58.2 ^b	85.9	5.0	3	2+3	5
3/ SM-102	184 ^b	85.9	15.8	3	200	5
4/ SM-102	500 ^a	100	50	3 0	3	5
5/ SM-102	1581 ^a	100	158	3 0	3	5
6/ SM-102	5000 ^a	100	500	3000	3	5
7/ SM-102	15811 ^a	100	1581	:10/3	3	5
8/ SM-102	50000 ^a	100	5000°	3	3	5
Positive controls	d	100	d o	3	3	5

- a Theoretical concentration; actual concentration may differ slightly due to the limitations of the instruments used.
- b Measured concentration
- c Test Item was tested at levels up to 5000 μ g/plate, which is the standard limit dose recommended by regulatory guidelines.
- d Dose depends on the test organism, the positive controls and methodology used (see Section 4.5.1.2)

Salmonella typhimurium strains (TA1535, TA1537, TA98, TA100) and Escherichia coli strain WP2 uvrA were treated with the Test Item at a range of concentrations up to 5000 μ g/plate (the standard limit dose for this assay), in the presence and absence of a supplemented rat liver fraction (S9 mix), using the plate incorporation version of the bacterial reverse mutation test.

Bacteria were incubated with standard positive controls, and the response of the various bacterial strains to these agents confirmed the sensitivity of the test system and the activity of the S9 mix.

Incomplete, or absent, background lawns of non-revertant bacteria, or substantial reductions in revertant colony counts, were not obtained following exposure to SM-102, indicating that the Test Item was non-toxic to the bacteria at the levels tested. Precipitation was observed at concentrations $\geq 1581~\mu g/plate$ in the absence of S9 mix and at concentrations $\geq 500~\mu g/plate$ in the presence of S9 mix.

No substantial increases in revertant colony numbers were obtained with any of the tester strains, following exposure to SM-102 at any dose level, in either the presence or absence of S9 mix.

It is concluded that SM-102 did not show any evidence of genotoxic activity in this in vitro mutagenicity assay when tested in accordance with regulatory guidelines.

3. INTRODUCTION

The objective of this study was to determine the potential genotoxicity of SM-102, using the

Guideline 471 and ICH Guideline S2(R1).

The Study Director signed the Study Plan on 08 Sep 2016, and dosing was initiated on 13 Sep 2016. The experimental start date was 12 Sep 2016, and the experimental completion date was 19 Sep 2016. The study was completed on the date of the Study Director appropriate signature page). The Study Director appropriate signature page). The Study Director appropriate signature page).

MATERIALS AND METHODS

4.1. Test and Reference Items

4.1.1. Test Item

Identification: SM-102

> Batch (Lot) No.: RL-100-211-1

95.72% (All concentrations and dose levels throughout this report Purity:

were corrected for purity using a purity of 95.3%.)

Kept in a freezer set to maintain -20°C **Storage Conditions:**

27 Oct 2017

4.1.2. Reference Items

4.1.2.1. Negative Control

Retest Date:

Ethanol Identification:

> Supplier: Commercial Alcohols

020612 Batch /Lot No **Expiration Date** June 2017

Storage Conditions: Kept at ambient room temperature

4.1.2.2. Positive Controls

In the absence of S9 mix:

Identity: Sodium azide (NaAz)

CAS number: 26628-22-8

Identity: 9-Aminoacridine hemihydrate (9AC)

65944-23-2 CAS number:

Identity: 2-Nitrofluorene (2NF)

CAS number: 607-57-8

Identity: 4-Nitroquinoline N-oxide (NQO)

CAS number: 56-57-5

In the presence of S9 mix:

Identity: 2-Aminoanthracene (2AA)

CAS number: 613-13-8

Identity: Benzo[a]pyrene (BaP)

CAS number: 50-32-8

Full details of positive controls including supplier, lot number, storage, expiry date and formulation are retained as part of the Test Facility records. Copies of certificates of analysis are retained as raw data.

4.2. Test Item Characterization

The Sponsor provided to the Test Facility documentation of the identity, strength, purity, composition, and stability for the Test Item. A Certificate of Analysis was provided to the Test Facility and is presented in Appendix 2.

4.3. Analysis of Test Item

A Certificate of Analysis was provided by the Sponsor and is presented in Appendix 2.

4.4. Test Item Inventory and Disposition

Records of the receipt, distribution, and storage of Test Item were maintained with the study raw data. All unused Test Item was returned to the Sponsor following completion of the experimental phase of the study. Any remaining Reference Items (negative and positive controls) will be retained at the Test Facility or discarded upon expiry.

4.5. Dose Formulation and Analysis

4.5.1. Preparation of Reference Items

4.5.1.1. Preparation of Negative Control

Control, ethanol, was dispensed into a via use. Any residual volumes were discarded before issuance of the Final Report.

4.5.1.2. Preparation of Positive Control

The An adequate amount of the Negative Control, ethanol, was dispensed into a vial for administration to control plates. The aliquot was stored in a refrigerator set to maintain 4°C until

The positive controls formulations were prepared up to 6 months prior to use. Adequate amounts were dispensed into vials, and stored in a freezer set to maintain -20°C, protected from light, until use. The aliquots were removed from the freezer and allowed to warm to ambient room temperature before dosing. Any residual volumes were discarded after completion of dosing.

Depending on the strains tested, the following positive controls were used:

Positive Controls for the Assay

Strain	S9	Positive Controls	Concentration µg/plate	Vehicle
TA1535, TA100		Sodium azide (NaAz)	0.5	Sterile water
TA1537	0	9-Aminoacridine hemihydrate (9AC)	50	DMSO
TA98	0	2-Nitrofluorene (2NF)	1	DMSO
WP2 uvrA		4-Nitroquinoline N-oxide (NQO)	0.5	DMSO
TA1535		2 A min conthuguena (2 A A)	5	DMCO
WP2 uvrA	+	2-Aminoanthracene (2AA)	20	BMSO
TA1537, TA98, TA100		Benzo[a]pyrene (BaP)	5	DMSO

4.5.2. Preparation of Test Item

The Test Item was prepared as a stock solution (50 mg/mL) in the chosen vehicle (ethanol) and all lower level formulations were made by serial dilution. The formulations were prepared 1 day prior to use and were stored in a refrigerator set to maintain 4°C until use. The formulations were removed from the refrigerator and allowed to warm to room temperature for at least 30 minutes before dosing. Any residual volumes were discarded before issuance of the Final Report.

4.5.3. Sample Collection and Analysis

The positive control formulations were not subjected to analysis for safety reasons and because the biological response of the test system is considered to be the best measure of the appropriateness of the formulations.

Dose formulations 1 to 8 were collected for concentration analysis only. Homogeneity, density and stability were not determined on these samples.

Samples to be analyzed were transferred at ambient room temperature, to the Analytical Chemistry department at the Test Facility on the date prepared. Any residual/retained analytical samples were discarded before issuance of the Final Report.

4.5.3.1. Analytical Method

Analyses were performed by HPLC, using a validated analytical procedure (Test Facility Study Number 1801841).

4.5.3.2. Concentration Analysis

Duplicate 1 mL samples for dose numbers 1 and 2 and duplicate 0.5 mL samples for dose numbers 3 to 8 were taken and sent to the analytical laboratory for analysis. Additional duplicate 1 mL samples for dose numbers 1 and 2 and duplicate 0.5 mL samples for dose numbers 3 to 8 were taken and retained at the Test Facility as backup samples. Concentration results were considered acceptable if mean sample concentration results were within $\pm 10\%$ of theoretical for the stock solution and $\pm 15\%$ of theoretical for lower level solutions. After acceptance of the analytical results, backup samples were discarded.

4.5.3.3. **Stability Analysis**

Stability analyses performed previously as part of a separate GLP-compliant study (Test Facility The bacteria were originally supplied by Moltox, NC, USA. Each batch of frozen bacteria was tested for appropriate phenotype characteristics and spontaneous reversion rates; response to diagnostic mutagens is also routinely assessed. The following bacterial strains.

S. typhimurium TA1535 hisG46 rfa AnomP

S. typhimurium TA Study Number 1801841) demonstrated that the Test Item is stable in the vehicle when prepared

- S. typhimurium TA98 hisD3052 rfa ∆uvrB pKM101
- S. typhimurium TA100 hisG46 rfa ∆uvrB pKM101
- E. coli WP2 trp uvrA

Fresh bacterial cultures were prepared so that they were in the late-log phase of growth at the time of use. The density of the cultures was confirmed to be $\geq 1000 \times 10^6$ bacteria/mL using a bacterial counting chamber before the cultures were used in the test.

4.6.1. Justification for Test System and Dose Level Selection

The bacterial reverse mutation test detects point mutations, which are the cause of many human genetic diseases and can play a role in tumor initiation and development.

Typically, the Test Item is dosed at a range of concentrations but is only assessed at the five highest levels below the toxic level or, if non-toxic, at five levels up to the standard limit of 5000 µg/plate.

4.7. S9 Mix

The S9 mix, used as a model of intact mammalian metabolism, was prepared on the day of use and contained 10% v/v S9 fraction (Aroclor 1254 induced male rat liver fraction supplied by Moltox) and the following sterile cofactors: 8 mM MgCl₂, 33 mM KCl, 100 mM sodium phosphate buffer pH 7.4, 5 mM glucose-6-phosphate and 4 mM NADP. The S9 mix was stored in a refrigerator set to maintain 4°C then held on ice during utilization. A copy of the manufacturer's quality control certificate for the S9 fraction is retained as raw data.

Sterility Check and Spontaneous Mutation Rates

This docura.8. The sterility of the Test Item formulation (high dose) was confirmed on the day of the test using appropriate preparations without bacteria.

> The spontaneous mutation rates of the bacterial strains were assessed using concurrent control samples in which the bacteria were exposed to the Negative Control.

4.9. Plate Incorporation Method

A 0.5 mL aliquot of S9 mix (+S9) or phosphate buffer 0.2 M pH 7.4 (0S9) was combined with 0.1 mL bacterial culture in a sterile container. An aliquot of the test item (see Text Table 2 for test item dose volumes) or a 0.1 mL aliquot of reference item was added, then 2 mL of molten top agar supplemented with 0.05 mM biotin and minimal (0.05 mM) histidine and minimal (0.05 mM) tryptophan was added immediately afterward. The solution was mixed and overlaid onto a minimal glucose plate (1.5% agar, Vogel-Bonner medium E, 2% glucose). After the overlay solidified, the plates were inverted and placed in an incubator set to maintain 37°C for 67 hours and 29 minutes.

4.10. Experimental Design

Text Table 2
Plate Incorporation Assay

	Formulation	Dose	Ti I.C	Number of	Replicates	
Dose No.	Conc. (μg/mL)	Volume (μL/plate)	Final Conc. (µg/plate)	089	+S9	Number of Strains
Negative Control	(μg/III <i>L)</i> -	100	- (μg/piate)	110 30 C	3	5
1/ SM-102	19.0 ^b	83,2	1.58	CO 13	3	5
2/ SM-102	58.2 ^b	85,9	5.0	3	3	5
3/ SM-102	184 ^b	85,9	25,8	3	3	5
4/ SM-102	500 ^a	100	o50 .0	3	3	5
5/ SM-102	1581ª	100	. 601580	3	3	5
6/ SM-102	5000 ^a	100	500	3	3	5
7/ SM-102	15811ª	100	1581	3	3	5
8/ SM-102	50000 ^a	0 100	5000°	3	3	5
Positive controls	d	100	d	3	3	5

- a Theoretical concentrations; actual concentrations may differ slightly due to the limitations of the instruments used.
- b Measured concentration
- c Test Item was tested at levels up to 5000 µg/plate, which is the standard limit dose recommended by regulatory guidelines.
- d Dose depends on the test organism, the positive controls and methodology used (see Section 4.5.1.2)

5. COMPUTERIZED SYSTEMS

Critical computerized systems used in the study are listed below or presented in the appropriate Phase Report. All computerized systems used in the conduct of this study have been validated; when a particular system has not satisfied all requirements, appropriate administrative and procedural controls were implemented to assure the quality and integrity of data.

Text Table 3	
Critical Computerized	Systems

System Name	Version No.	Description of Data Collected and/or Analyzed
Sorcerer (Perceptive Instruments)	2.2	Revertant colony counts
Microsoft® Excel	2007	Descriptive statistics of revertant colony counts data.
Mesa Laboratories AmegaView CMS	v3.0 Build 1208.8	Continuous Monitoring System. Monitoring of standalone fridges, freezers, incubators, and selected laboratories to measure temperature, relative humidity, and CO ₂ , as appropriate.
Johnson Controls Metasys	MVE 5.4 (M5)	Building Automation System. Control of HVAC and other building systems, as well as temperature/humidity control and trending in selected laboratories.

6. EVALUATION AND INTERPRETATION OF RESULTS

After the incubation period, the plates from bacterial reverse mutation test were examined visually; an inverted microscope was also employed to facilitate observations. Plates were evaluated for the quality of the background lawn and the number of revertant colonies. Revertant colony counts were collected and saved directly into an electronic database using an automated colony counter. Colony numbers were enumerated visually if precipitation or other artifacts interfered with the colony counter or at the discretion of the Study Director. The presence of visible precipitate was manually recorded in the raw data. Visual counts were performed for this study.

Toxic effects of the Test Item are normally indicated by the partial or complete absence of a background lawn (colony counts, if any, are not reported) or a substantial dose-related reduction in revertant colony counts compared with lower dose levels and concurrent Negative Control (i.e. fold response < 0.6) taking into account the laboratory historical control range.

The mean number of revertant colonies for all treatment groups was compared with those obtained for the concurrent Negative Control level.

6.1. Assay Acceptance Criteria:

Acceptable Negative Control: The number of revertants must be within or close the current historical negative control range of the laboratory.

Acceptable Positive Control: The mean value of a Positive Control for a tester strain must be compatible with those generated in the historical positive control data base and be substantially higher (≥ 2-fold) than the mean number of revertant colonies for its respective Negative Control.

Acceptable highest dose: Depending on the nature of the Test Item, it should reach the toxicity limit, but not exceed 5000 µg/plate, with at least 5 analyzable concentrations, if available.

In the event that the controls fall slightly and it.

In the event that the controls fall slightly outside the normal range (historical or Study Plan), the Study Director was allowed discretion to accept the results of the experiment as valid based on the biological significance.



6.2. Interpretation of Results

Biological relevance of the results was considered first.

Negative result (no evidence of genotoxicity) is concluded if there is no substantial increase (< 2-fold) in the number of colonies per plate in comparison to the concurrent Negative Control and the data is within or close to the 98% tolerance limit of the Negative Historical Control data. A negative result indicates that the Test Item is non-mutagenic in S. typhimurium and E. coli.

Positive result (evidence of genotoxicity) is concluded if there is a substantial increase (\geq 2-fold) in the number of colonies per plate in comparison to the concurrent Negative Control, the mean values are above the 98% tolerance limit of the Negative Historical Control data and a concentration-related increase over the exposure range tested is obtained. A positive result indicates that the Test Item induces point mutations in S. typhimurium and/or E. coli.

Equivocal result is concluded if no definite judgment can be made to fit the above criteria. An equivocal result indicates that a definitive conclusion cannot be made by performing the bacterial reverse mutation assay under the conditions described in the Study Plan. Alternate testing conditions (e.g., a narrower dose interval with the appropriate strain) may be used as an aid in evaluating the test results.

7. RETENTION OF RECORDS

All study-specific raw data, documentation, Study Plan, and final report from this study were archived at the Test Facility by no later than the date of final report issue. One year after issue of the unaudited Draft Report, the Sponsor will be contacted to determine the disposition of materials associated with the study.

Electronic data generated by the Test Facility were archived as noted above, except the reporting files stored on SDMS, which were archived at the Charles River Laboratories facility location in Wilmington, MA.

8. RESULTS

8.1. Dose Formulation Analyses

Results of the dose formulation analyses are presented in Appendix 4.

The five highest formulation concentrations ranging from 500 to 50000 μ g/mL met acceptance criteria, with chemical analysis indicating mean achieved concentrations within $\pm 10\%$ of the theoretical concentration for the stock solution and $\pm 15\%$ for lower level solutions. The lowest three formulation concentrations did not meet acceptance criteria (dose number 1 was $\pm 20\%$ of nominal, dose number 2 was $\pm 16\%$ of nominal and dose number 3 was $\pm 16\%$ of nominal). Analyses of the retention samples were not performed due to the consistency of the results of the duplicate samples. Instead the results were accepted and the dose volumes of the three lowest test item concentrations to be tested were adjusted accordingly to obtain the concentrations specified in the study plan.

8.2. Bacterial Mutation Test

Results of the bacterial mutation test are presented in Table 1, Table 2 and Table 3; the mean and standard deviation values quoted have been rounded to the nearest whole number.

The absence of colonies on sterility check plate confirmed absence of microbial contamination (results not shown). The mean revertant colony counts for the Negative Control were within the laboratory historical control range (see Appendix 3 for individual colony count historical results). Appropriate positive controls (with S9 mix where required) induced increases in revertant colony numbers to at least twice the concurrent Negative Control levels with the appropriate bacterial strain, confirming sensitivity of the test system and activity of the S9 mix (see also Appendix 3 for positive controls historical results).

Incomplete, or absent, background lawns of non-revertant bacteria, or substantial reductions in revertant colony counts, were not obtained following exposure to SM-102, indicating that the Test Item was non-toxic to the bacteria at the levels tested. Precipitation was observed at concentrations $\geq 1581~\mu g/plate$ in the absence of S9 mix and at concentrations $\geq 500~\mu g/plate$ in the presence of S9 mix.

No substantial increases in revertant colony numbers were obtained with any of the tester strains, following exposure to SM-102 at any dose level, in either the presence or absence of S9 mix. Therefore, SM-102 was considered to be negative for the induction of mutagenicity in this in vitro assay.

This drot that the leggle send that the leggle send that the land that the land the leggle send that the land the leggle send that the land the land that the land the land that the land the la

Table 1 SM-102 - Plate Incorporation Assay in the Absence of S9 Mix

Fold esponse † .0 .3 .0 .4 .5 .3 .9 .1 .0 .3
.0 .3 .0 .4 .5 .3 .9 .1 .0
.3 .0 .4 .5 .3 0.9 .1 .0
.1 .0 .3
0
3
.5
.2
0
1
0.8
).9
3
0
).9
0
0.8
0.8
).7
).7
0.8
).7
).).).

Comments on the plate or background lawn: precipitate (ppt)

Fold response in mean revertants compared to concurrent Negative Control.

Table 1 SM-102 - Plate Incorporation Assay in the Absence of S9 Mix (Cont'd)

Strain	Conc.	S9	N	Jumbe	er of re	evertant	s	Plate	observat	ions *	Fold
	(µg/plate)		x_1	x_2	x_3	mean	SD	x_1	x_2	x_3	response *
TA100	Ethanol	0	134	124	142	133	9				1.0
	1.58	0	125	126	106	119	11				0.9
	5.0	0	126	126	117	123	5				0.9
	15.8	0	126	131	125	127	3				0.9 0.9 1.0 0.9 0.7 0.9 0.8 1.0 0.8 0.9 0.9 0.7 0.8 0.8 0.9
	50	0	108	127	109	115	11				0.9
	158	0	97	112	137	115	20				0.9
	500	0	106	85	106	99	12				0.7
	1581	0	122	113	118	118	5	ppt	ppt	ppt	0.9
	5000	0	124	116	86	109	20	ppt	ppt	ppt	0.8
WP2 uvrA	Ethanol	0	62	63	51	59	7	• • •	•	ton!	1.0
	1.58	0	55	29	56	47	15		1	200	0.8
	5.0	0	50	44	43	46	4		70,00	es l'	0.8
	15.8	0	64	50	46	53	9		Sup Mp		0.9
	50	0	51	58	52		4	20:	CO.		0.9
	158	0	41	41	43	42	4 1 6	COLUMN S	00		0.7
	500	0	41	52	41	45	6.0	10 -0.1			0.8
	1581	0	43	47	52	47	35	\nnt	nnt	nnt	0.8
	5000	ő	52	55	42	₹50°C	10E	ppt	ppt	ppt	0.8
					\mathcal{O} . ()	. 1					
				Weill		, ,					
	·C	POKE	el be	All dill	20	, ,					
* Comments † Fold responsible SD Standard de	aused to sur	Port ?	of Pee	dillouille distribution di la constanti di la							

Comments on the plate or background lawn: precipitate (ppt)

Fold response in mean revertants compared to concurrent Negative Control.

Table 2 SM-102 - Plate Incorporation Assay in the Presence of S9 Mix

in												
	Conc.	S9	N	umbe	r of re	vertant		Plate	observati	ons *	Fold	
	(μg/plate)		x_1	x_2	x_3	mean		x_{I}	x_2	x_3	respons	e †
35	Ethanol	+	32	29	22	28	5				1.0	
	1.58	+	14	23	20	19	5				0.7	C
	5.0	+	24	13	19	19	6				0.7	:00:
	15.8	+	28	25	22	25	3				0.9	
		+									0.8	
		+									0.8	
		+						ppt	ppt	ppt	0.8	
		+					5	ppt	ppt	ppt	0.7	
		+					2	ppt	ppt	ppt	0.8	
37		+					1		, e	T. W	1.0	
		+					3		Kng	, V	0.7	
		+					4		2000		0.6	
		+					3		SI, Olli		1.2	
		+					4	10/	Second		1.0	
						19	0	30° /			1.2	
				14	15	16	30	ppt	ppt	ppt		
				12	13	11	3,0	ppt	ppt	ppt		
				10	18	∂1 <u>5</u> ;(0	40	ppt	ppt	ppt		
8				59	600	53	%11					
				51	67	○.28 <i>∕</i> ○	8					
				20,	_ئورچ	40	13					
					_							
				1 / 1								
		. 16	/ ^ V /									
		()					3	ppt	ppt	ppt	1.0	
•		50 158 500 1581 5000 37 Ethanol 1.58 5.0 15.8 50 158 500 1581 5000 8 Ethanol 1.58 5.0 15.8 5.0 15.8 500 1581 5000 15.8 500 15.8	50 + 158 + 500 + 1581 + 5000 + 37 Ethanol + 1.58 + 5.0 + 15.8 + 50 + 158 + 500 + 1581 + 5000 + 1581 + 5000 + 1588 + 50 + 158 + 50 + 158 + 50 + 158 + 50 + 158 + 50 + 158 + 50 + 158 + 50 + 158 + 50 + 158 + 50 + 158 + 50 + 158 + 50 + 158 + 500 + 1581 + 5000 + 1581 + 5000 + 1581 + 5000 + 1581 + 5000 + 1581 + 5000 + 1581 + 5000 + 1581 + 5000 + 1581 + 5000 + 1581 + 5000 + 1581 + 5000 +	50 + 28 158 + 18 500 + 22 1581 + 17 5000 + 21 37 Ethanol + 15 1.58 + 8 5.0 + 14 15.8 + 20 50 + 18 158 + 19 500 + 19 1581 + 8 5000 + 17 8 Ethanol + 41 1.58 + 55 5.0 + 61 15.8 + 55 5.0 + 61 15.8 + 58 50 + 51 15.8 + 67 500 + 53 1581 + 67 5000 + 49 ments on the plate or background 1	50 + 28 14 158 + 18 19 500 + 22 22 1581 + 17 24 5000 + 21 23 37 Ethanol + 15 15 1.58 + 8 11 5.0 + 14 10 15.8 + 20 20 50 + 18 17 158 + 19 19 500 + 19 14 1581 + 8 12 5000 + 17 10 8 Ethanol + 41 59 1.58 + 55 51 5.0 + 61 38 15.8 + 58 58 50 + 51 39 158 + 46 46 500 + 53 57 1581 + 67 52 5000 + 49 50 ments on the plate or background lawn: presents in means in	50 + 28 14 27 158 + 18 19 27 500 + 22 22 25 1581 + 17 24 15 5000 + 21 23 20 37 Ethanol + 15 15 17 1.58 + 8 11 13 5.0 + 14 10 6 15.8 + 20 20 15 50 + 18 17 10 158 + 19 19 19 500 + 19 14 15 1581 + 8 12 13 5000 + 17 10 18 8 Ethanol + 41 59 60 1.58 + 55 51 67 5.0 + 61 38 38 15.8 + 58 58 38 50 + 51 39 56 158 + 46 46 46 500 + 53 57 44 1581 + 67 52 68 5000 + 49 50 54 ments on the plate or background lawn: precipita	50 + 28 14 27 23 158 + 18 19 27 21 500 + 22 22 25 23 1581 + 17 24 15 19 5000 + 21 23 20 21 37 Ethanol + 15 15 17 16 1.58 + 8 11 13 11 5.0 + 14 10 6 10 15.8 + 20 20 15 18 50 + 18 17 10 15 158 + 19 19 19 19 500 + 19 14 15 16 1581 + 8 12 13 11 5000 + 17 10 18 15 8 Ethanol + 41 59 60 53 1.58 + 55 51 67 58 5.0 + 61 38 38 46 15.8 + 58 58 38 51 50 + 51 39 56 49 158 + 46 46 46 46 500 + 53 57 44 51 1581 + 67 52 68 62 5000 + 49 50 54 51	50 + 28 14 27 23 8 158 + 18 19 27 21 5 500 + 22 22 25 23 2 1581 + 17 24 15 19 5 5000 + 21 23 20 21 2 37 Ethanol + 15 15 17 16 1 1.58 + 8 11 13 11 3 5.0 + 14 10 6 10 4 15.8 + 20 20 15 18 3 50 + 18 17 10 15 4 158 + 19 19 19 19 0 500 + 19 14 15 16 3 1581 + 8 12 13 11 3 5000 + 17 10 18 15 4 8 Ethanol + 41 59 60 53 11 1.58 + 55 51 67 58 8 5.0 + 61 38 38 46 13 15.8 + 58 58 38 51 12 50 + 51 39 56 49 9 158 + 46 46 46 46 0 500 + 53 57 44 51 7 1581 + 67 52 68 62 9 5000 + 49 50 54 51 3	50 + 28 14 27 23 8 158 + 18 19 27 21 5 500 + 22 22 25 23 2 ppt 1581 + 17 24 15 19 5 ppt 5000 + 21 23 20 21 2 ppt 37 Ethanol + 15 15 17 16 1 1.58 + 8 11 13 11 3 5.0 + 14 10 6 10 4 15.8 + 20 20 15 18 3 50 + 18 17 10 15 4 158 + 19 19 19 19 0 500 + 19 14 15 16 3 ppt 1581 + 8 12 13 11 3 ppt 5000 + 17 10 18 15 4 1581 + 8 12 13 11 3 ppt 5000 + 17 10 18 15 4 8 Ethanol + 41 59 60 53 11 1.58 + 55 51 67 58 8 5.0 + 61 38 38 46 13 15.8 + 58 58 38 51 12 50 + 51 39 56 49 9 158 + 46 46 46 46 46 0 500 + 53 57 44 51 7 ppt 1581 + 67 52 68 62 9 ppt 5000 + 49 50 54 51 3 ppt ments on the plate or background lawn: precipitate (ppt)	50 + 28 14 27 23 8 158 + 18 19 27 21 5 500 + 22 22 25 23 2 ppt ppt 1581 + 17 24 15 19 5 ppt ppt 5000 + 21 23 20 21 2 ppt ppt 37 Ethanol + 15 15 17 16 1 1.58 + 8 11 13 11 3 5.0 + 14 10 6 10 4 15.8 + 20 20 15 18 3 50 + 18 17 10 15 4 158 + 19 19 19 19 0 500 + 19 14 15 16 3 ppt ppt 1581 + 8 12 13 11 3 ppt ppt 1581 + 8 12 13 11 3 ppt ppt 1581 + 8 12 13 11 3 ppt ppt 1581 + 8 12 13 11 3 ppt ppt 1583 + 55 51 67 58 8 5.0 + 61 38 38 46 13 15.8 + 58 58 38 51 12 50 + 51 39 56 49 9 158 + 46 46 46 46 0 500 + 53 57 44 51 7 ppt ppt 1581 + 67 52 68 62 9 ppt ppt 5000 + 49 50 54 51 3 ppt ppt	50 + 28 14 27 23 8 158 + 18 19 27 21 5 500 + 22 22 25 23 2 ppt ppt ppt 1581 + 17 24 15 19 5 ppt ppt ppt 5000 + 21 23 20 21 2 ppt ppt ppt 5000 + 21 13 11 3 Ethanol + 15 15 17 16 1 1.58 + 8 11 13 11 3 5.0 + 14 10 6 10 4 15.8 + 20 20 15 18 3 50 + 18 17 10 15 4 158 + 19 19 19 19 0 500 + 19 14 15 16 3 ppt ppt ppt 1581 + 8 12 13 11 3 ppt ppt ppt 5000 + 17 10 18 15 4 1.58 + 55 51 67 58 8 5.0 + 61 38 38 46 13 15.8 + 58 58 38 51 12 50 + 51 39 56 49 9 1581 + 67 52 68 62 9 ppt ppt ppt ments on the plate or background lawn: precipitate (ppt)	50 + 28 14 27 23 8 0.8 158 + 18 19 27 21 5 0.8 500 + 22 22 25 23 2 ppt ppt ppt 0.8 1581 + 17 24 15 19 5 ppt ppt ppt 0.7 5000 + 21 23 20 21 2 ppt ppt ppt 0.8 37 Ethanol + 15 15 17 16 1 1.0 1.58 + 8 11 13 11 3 0.7 5.0 + 14 10 6 10 4 0.6 15.8 + 20 20 15 18 3 1.2 50 + 18 17 10 15 4 1.0 158 + 19 19 19 19 0 1.2 500 + 19 14 15 16 3 ppt ppt ppt ppt 0.7 5000 + 17 10 18 15 4 ppt ppt ppt 0.7 5000 + 17 10 18 15 4 ppt ppt ppt 1.0 1581 + 8 12 13 11 3 ppt ppt ppt 0.7 5000 + 17 10 18 15 4 ppt ppt ppt 0.7 5000 + 17 10 18 15 4 ppt ppt ppt 0.7 5000 + 17 10 18 15 4 ppt ppt ppt 0.7 5000 + 17 10 18 15 4 ppt ppt ppt 0.7 5000 + 17 10 18 15 4 ppt ppt ppt 0.7 5000 + 17 10 18 15 10 ppt ppt ppt 0.7 5000 + 17 10 18 15 10 ppt ppt ppt 0.7 5000 + 17 10 18 15 10 ppt ppt ppt 0.7 5000 + 17 10 18 15 10 ppt ppt ppt 1.0 1.58 + 55 51 67 58 8 1.1 5.0 + 61 38 38 46 13 0.9 15.8 + 58 58 38 51 12 1.0 50 + 51 39 56 49 9 0.9 158 + 46 46 46 46 46 0 0.9 500 + 53 57 44 51 7 ppt ppt ppt ppt 1.0 1581 + 67 52 68 62 9 ppt ppt ppt ppt 1.0 ments on the plate or background lawn: precipitate (ppt)

Comments on the plate or background lawn: precipitate (ppt)

Fold response in mean revertants compared to concurrent Negative Control.

Table 2 SM-102 - Plate Incorporation Assay in the Presence of S9 Mix (Cont'd)

Conc. (µg/plate) Ethanol 1.58 5.0 15.8 50 158 500 1581	+ + + + + +	N x ₁ 169 150 151 174 165 135 141	144 123 155 172	154 153 136 160 156	156 142 147 169 158		Plate x_I	observati x_2	<i>x</i> ₃	Fold response † 1.0 0.9 0.9 1.1 1.0 0.9 0.8 1.0 1.0 1.0
Ethanol 1.58 5.0 15.8 50 158 500 1581	+ + + + + +	169 150 151 174 165 135	144 123 155 172 153	154 153 136 160 156	156 142 147 169	13 17 10 8	x_1			1.0
1.58 5.0 15.8 50 158 500 1581	+ + + + + +	150 151 174 165 135	123 155 172 153	153 136 160 156	142 147 169	17 10 8				
5.0 15.8 50 158 500 1581	+ + + + +	151 174 165 135	155 172 153	136 160 156	147 169	10 8				0.9 0.9 1.1
15.8 50 158 500 1581	+ + +	174 165 135	172 153	160 156	169	8				0.9 1.1
50 158 500 1581	+ + +	165 135	153	156						1.1
158 500 1581	++	135			158	6				
500 1581	+		131							1.0
1581		1/1		131	132	2				0.9
1581		141	130	123	131	9	ppt	ppt	ppt	0.8
	+	146	156	163	155	9	ppt	ppt	ppt	1.0
5000	+	160	141	157	153	10	ppt	ppt	ppt	1.0
Ethanol	+	49	55	62	55	7		, 0	t w	1.0
1.58	+	51	60	50	54	6		Kno	, D.	1.0
5.0	+	43	62	65	57	12		9,00		1.0
15.8	+	55	57	61	58	3		SIL SILLE		1.0
50	+	53	58	60	57	4	10/1	~6CC		1.0
158	+	53	52	43	49	6	COL.			0.9
500	+	39	36	53	43	90	ppt	ppt	ppt	0.8
1581	+	63	48	44	52	10	ppt	ppt	ppt	0.9
5000	+	47	38	38	⊘41 ;⊘	` (50)`	ppt	ppt		0.7
he used to sur	Port of June	et be	and the state of t	,),						
	Ethanol 1.58 5.0 15.8 50 158 500 1581 5000 s on the plate or onse in mean revideviation	Ethanol + 1.58 + 5.0 + 15.8 + 50 + 158 + 500 + 1581 + 5000 + s on the plate or backgonse in mean revertants deviation	Ethanol + 49 1.58 + 51 5.0 + 43 15.8 + 55 50 + 53 158 + 53 500 + 39 1581 + 63 5000 + 47 s on the plate or background bonse in mean revertants compensation	Ethanol + 49 55 1.58 + 51 60 5.0 + 43 62 15.8 + 55 57 50 + 53 58 158 + 53 52 500 + 39 36 1581 + 63 48 5000 + 47 38 s on the plate or background lawn: ponse in mean revertants compared to deviation	Ethanol + 49 55 62 1.58 + 51 60 50 5.0 + 43 62 65 15.8 + 55 57 61 50 + 53 58 60 158 + 53 52 43 500 + 39 36 53 1581 + 63 48 44 5000 + 47 38 38 s on the plate or background lawn: precipitationse in mean revertants compared to concur deviation	Ethanol + 49 55 62 55 1.58 + 51 60 50 54 5.0 + 43 62 65 57 15.8 + 55 57 61 58 50 + 53 58 60 57 158 + 53 52 43 49 500 + 39 36 53 43 1581 + 63 48 44 52 5000 + 47 38 38 41 s on the plate or background lawn: precipitate (ppt) onse in mean revertants compared to concurrent Negrodeviation	Ethanol + 49 55 62 55 7 1.58 + 51 60 50 54 6 5.0 + 43 62 65 57 12 15.8 + 55 57 61 58 3 50 + 53 58 60 57 4 158 + 53 52 43 49 6 500 + 39 36 53 43 9 1581 + 63 48 44 52 10 5000 + 47 38 38 41 5 s on the plate or background lawn: precipitate (ppt) conse in mean revertants compared to concurrent Negative Condeviation	Ethanol + 49 55 62 55 7 1.58 + 51 60 50 54 6 5.0 + 43 62 65 57 12 15.8 + 55 57 61 58 3 50 + 53 58 60 57 4 158 + 53 52 43 49 6 500 + 39 36 53 43 9 ppt 1581 + 63 48 44 52 10 ppt 5000 + 47 38 38 41 5 ppt s on the plate or background lawn: precipitate (ppt) onse in mean revertants compared to concurrent Negative Control. deviation	5000 + 160 141 157 153 10 ppt ppt Ethanol + 49 55 62 55 7 1.58 + 51 60 50 54 6 5.0 + 43 62 65 57 12 15.8 + 55 57 61 58 3 50 + 53 58 60 57 4 158 + 53 52 43 49 6 500 + 39 36 53 43 9 ppt ppt 1581 + 63 48 44 52 10 ppt ppt 5000 + 47 38 38 41 5 ppt ppt s on the plate or background lawn: precipitate (ppt) onse in mean revertants compared to concurrent Negative Control. deviation	1581 + 146 156 163 155 9 ppt ppt ppt 5000 + 160 141 157 153 10 ppt ppt ppt ppt 1.58 + 49 55 62 55 7 1.58 + 51 60 50 54 6 5.0 + 43 62 65 57 12 15.8 + 53 52 43 49 6 500 + 39 36 53 43 9 ppt ppt ppt 1581 + 63 48 44 52 10 ppt ppt ppt 5000 + 47 38 38 41 5 ppt ppt ppt son the plate or background lawn: precipitate (ppt) sonse in mean revertants compared to concurrent Negative Control.

Comments on the plate or background lawn: precipitate (ppt)

Fold response in mean revertants compared to concurrent Negative Control.

Table 3 **Positive Controls for the Plate Incorporation Assay**

	Strain	T 44								
		Treatment	Conc.	S9		Numbe	er of rev	ertants		Fold
			(µg/plate)		x_1	x_2	x_3	mean	SD	response
_	TA1535	NaAz	0.5	0	398	409	395	401	7	28
	TA1537	9AC	50	0	357	40 1	423	394	34	42 4.8 3.9 3.5 9.1 6.9
	TA98	2NF	1	0	195	228	173	199	28	4.8
	TA100	NaAz	0.5	0	524	518	500	514	12	3.9
	WP2 uvrA	NQO	0.5	0	191	197	222	203	16	3.5
										9 1
	TA1537	BaP	5	+	128	84	112	108	12 22 11 14	6.9
	TA1937	Dar	5		244	261	261	100 256	11 %	6.7
	1A90	Dar D-D	5	T .	042	30 4	201	330 050	118	6.7
	1A100	BaP	3	+	942	969	963	958	134 V	6.2
_	WP2 uvrA	2AA	20	+	202	190	216	203 ⊘	130	3.7
						200	II OR			
				JIK.	Paisa	100 PO	2,			
				3. 97. 3. 671.	indisa,	ion 120	5			
			y marketil	on the state of th	indies,	ion 201	5``			
			t and house on the state of the	on the	inorisa inorisa inorisa	100 NO	5`			
		TO SUPPO	inder Redulation	on the state of th	JR 2 EN LINGTON	049120	5`			
		used to suppo	t and hat be driven	on the state of th	JRacia JRacia	049120				
	%	used to suppo	t any marketilati	on the	inorisa inorisa inorisa	0491205				
	, O't W ^O	used to suppo	t any marketil	on the series	JRaisa JRaisa JRaisa	049120				
	annothe	Jsed to suppo	nder Redulati	on the state of th	in Ao	04.9120				
	nt cannot be	used to suppose	inder Redulation	on the	DRA PARTIES AND	0491205				
	ant cannot be	used to suppo	t and realitations and the state of the stat	on the series	JRaisa JRaisa JRaisa	049120				
CILL	ant cannot be	Jsed to suppo	inder Redulati	on the state of th		000000000000000000000000000000000000000				
Jocum	ant cannot be	used to suppo	th any marketil	a auticon	DRA STAN	000000000000000000000000000000000000000				
OCUM	ent cannot be	Jeg pole ased	t any marketil	on the state of th	JRa est	0491205				
ocume	ant cannot be	Jeg dio suppo	A STY Marketil	on the solution of the solutio	JRaisa JRaisa JRaisa	000000000000000000000000000000000000000				
OCUM	ant cannot be	used to suppo	t any marketil	on the state of th		000000000000000000000000000000000000000				
Bociting	ent cannot be	used to suppos	it and marketilation	on the state of th	DRA ENTRA DE LA COMPANSION DE LA COMPANS	0491205				
Bochul	ant cannot be	2AA BaP BaP BaP 2AA se in mean revertaviation	t and redulation	on the series	JRaisa JRaisa JRaisa JRaisa	000000000000000000000000000000000000000				